Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Investing.com -- Novo Nordisk (CSE: NOVOb) (NYSE: NVO) shares slumped Wednesday after Roche (SIX: ROG) struck a $5.3 billion ...

Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...